Download PDF
Thromb Haemost 2009; 101(02): 279-283
DOI: 10.1160/TH08-10-0659
Clinical Focus
Schattauer GmbH

Heparin-induced thrombocytopenia: What clinicians need to know

Beng H. Chong
1   Department of Haematology, SEALS, St George Hospital, and Centre of Vascular Research, Department of Medicine, St George Clinical School, University of New South Wales, Sydney, Australia
,
Arend Isaacs
1   Department of Haematology, SEALS, St George Hospital, and Centre of Vascular Research, Department of Medicine, St George Clinical School, University of New South Wales, Sydney, Australia
› Author Affiliations
Further Information

Publication History

Received: 11 October 2008

Accepted after minor revision: 29 January 2008

Publication Date:
23 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Chong BH. Heparin-induced thrombocytopenia. In: Platelets. (2nd Edition) Academic Press; New York: 2007: 861-866.
    CrossrefGoogle Scholar
  • 2 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-1478.
    CrossrefPubMedGoogle Scholar
  • 3 Warkentin TE, Greinacher A, Koster A. et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 Suppl 340S-380S.
    CrossrefPubMedGoogle Scholar
  • 4 Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2: 148-157.
    PubMedGoogle Scholar
  • 5 Newman P, Chong BH. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resulting activation. Blood 2000; 96: 182-187.
    PubMedGoogle Scholar
  • 6 Savi P, Chong BH, Greinacher A. et al. Effect of Fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicentre study with unfractionated heparin. Blood 2005; 105: 139-144.
    CrossrefPubMedGoogle Scholar
  • 7 Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular weight heparin-induced HIT: a case report. Thromb Haemost 2008; 99: 779-781.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Schindewolf M, Lindhoff-Last E. Fondaparinux-related thrombocytopenia in a patient with former HIT. Response to Rota et al. Thromb Haemost 2008; 100: 168-169.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Majed AR, Warkentin TE, Axelson M. et al. Delayed-onset heparin-induced thrombocytopenia, venous thromboembolism, and cerebral venous thrombosis: A consequence of heparin “flushes”. Thromb Haemost 2007; 98: 1139-1140.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Chong BH, Du X-P, Berndt MC. et al. Characterisation of the binding domains on platelet glycoproteins Ib-IX and IIb/IIIa complexes for the quinine/quinidine-dependent antibodies. Blood 1991; 77: 2190-2199.
    CrossrefPubMedGoogle Scholar
  • 11 Gustavo OBF, Crespo EM, Becker RC. et al for the Complications after thrombocytopenia caused by heparin (CATCH) Registry Investigators. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med 2008; 168: 94-102.
    CrossrefPubMedGoogle Scholar
  • 12 Price EA, Hayward CPM, Moffat KA. et al. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories. Thromb Haemost 2007; 98: 1357-1361.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Chong BH, Gallus AS, Cade J. et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost, 2001; 86: 1170-1175.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Magnani HN, Gallus A. Heparin-induced thrombocytopenia(HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95: 967-981.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Farner B, Eichler P, Kroll H. et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Throm Haemost 2001; 85: 950-957.
    PubMedGoogle Scholar
  • 16 Keng TB, Chong BH. Heparin-induced thrombocytopenia and thrombosis syndrome: invivo cross-reactivity with danaparoid and successful treatment with r-Hirudin. Brit J Haemotol 2001; 114: 394-396.
    PubMedGoogle Scholar
  • 17 Warkentin TE. Fondaparinux versus direct thrombin inhibitor therapy for the managemetnof heprin-induced thrombocytopenia (HIT) – Bridging the River Coumarin. Thromb Haemost 2008; 99: 2-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Lobo B, Finch C, Howard A. et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 2008; 99: 208-214.
    Article in Thieme ConnectPubMedGoogle Scholar